Below are the most recent publications written about "Azasteroids" by people in Profiles.
-
Tziotzios C, Fenton DA, Stefanato CM, McGrath JA. Finasteride is of uncertain utility in treating frontal fibrosing alopecia. J Am Acad Dermatol. 2016 Apr; 74(4):e73-4.
-
Chu FM, Sartor O, Gomella L, Rudo T, Somerville MC, Hereghty B, Manyak MJ. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer. Eur J Cancer. 2015 Aug; 51(12):1555-69.
-
Andriole GL, Bostwick DG, Gomella LG, Marberger M, Montorsi F, Tammela TL, Tindall DJ, Fowler IL, Garges HP, Wilson TH, Castro R. Modeling and analysis of Gleason score 8-10 prostate cancers in the REDUCE study. Urology. 2014 Aug; 84(2):393-9.
-
Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery B. Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol. 2014 Jan 20; 32(3):229-37.
-
Halpern EJ, Gomella LG, Forsberg F, McCue PA, Trabulsi EJ. Contrast enhanced transrectal ultrasound for the detection of prostate cancer: a randomized, double-blind trial of dutasteride pretreatment. J Urol. 2012 Nov; 188(5):1739-45.
-
Andriole GL, Bostwick D, Brawley OW, Gomella L, Marberger M, Montorsi F, Pettaway C, Tammela TL, Teloken C, Tindall D, Freedland SJ, Somerville MC, Wilson TH, Fowler I, Castro R, Rittmaster RS. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol. 2011 Jan; 185(1):126-31.
-
Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010 Apr 01; 362(13):1192-202.
-
Sartor O, Gomella LG, Gagnier P, Melich K, Dann R. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. Can J Urol. 2009 Oct; 16(5):4806-12.
-
Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja SS, Lucia MS, Wolford E, Somerville MC, Rittmaster R. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials. 2007 Nov; 28(6):763-9.
-
Mitterberger M, Pinggera G, Horninger W, Strasser H, Halpern E, Pallwein L, Gradl J, Bartsch G, Frauscher F. Dutasteride prior to contrast-enhanced colour Doppler ultrasound prostate biopsy increases prostate cancer detection. Eur Urol. 2008 Jan; 53(1):112-7.